This is a demo store. No orders will be fulfilled.

Life Sciences

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

  1. 12 Aug 2021  |  North America

    Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021

    A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

    Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPTs debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving ac...

    $4,950.00
  2. 23 Jun 2021  |  Global

    Frost Radar™: Artificial Intelligence-enabled Drug Discovery in the Global Pharmaceutical Industry, 2021

    A Benchmarking System to Spark Companies to Action—Innovation that Fuels New Deal Flow and Growth Pipelines

    Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

    $4,950.00
  3. 03 Nov 2020  |  North America

    Frost Radar™: Global Full Product Development CMO in the IVD Industry, 2020

    A Benchmarking System to Spark Companies to Action—Innovation That Fuels New Deal Flow and Growth Pipelines

    Full product development IVD CMO comprises companies that partner with OEMs and support them in the development of IVD devices, ranging from concept to commercialization. IVD companies are continuously looking at new ways to optimize resources due to rising cost pressures and regulatory complexities, prompting industry participants to adopt innovat...

    $4,950.00
  4. 27 Aug 2020  |  Global

    Smart Labs as Key Drivers for the Digital Transformation of Diagnostic Laboratories, 2020

    Robotic Automation, Internet of Things (IoT), and Artificial Intelligence (AI) Offering Growth Opportunities for Academic and Commercial Diagnostics Labs

    Diagnostic academic and commercial research labs suffer from cost pressures, given the ongoing Protecting Access to Medicare Act (PAMA) regulations and reproducibility issues, and are under productivity strain. The recent COVID-19 pandemic leading to increasing test volumes and renewed focus on research and development (R&D) to drive innovation wil...

    $3,000.00
  5. 05 May 2020  |  North America

    FROST RADAR™: Artificial Intelligence for Drug Discovery in the Pharmaceutical Industry, 2020

    Benchmarking Future Growth Potential

    Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...

    $4,950.00
  6. 31 Jan 2020  |  North America

    Predictions for the Global Life Sciences Industry, 2020

    COVID-19 Pandemic will Drive New Digital-tech Adoption in Drug Discovery and Testing Services, and Federal Funding will Encourage Stronger Product Pipelines

    The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

    $1,500.00
  7. 27 Jan 2020  |  Global

    Growth Opportunities—Contract Manufacturing and Outsourcing Opportunities in the In-vitro Diagnostics (IVD) Industry, 2019 to 2022

    Consolidation and Innovative Business Models Will Accelerate IVD Outsourcing Growth

    The increasing pressure for cost-driven development and regulatory and regional trends are inducing industry participants to adopt innovative integrated business models so as to align themselves as one-stop-shop solution providers as opposed to the traditional functional service providers, thereby, creating a mutually beneficial symbiotic relations...

    $4,950.00
  8. 10 Jan 2020  |  Asia Pacific

    Growth Insights on China’s Pharmaceutical Industry, Forecast to 2025

    Expedited Regulatory Reviews, Accompanied by Surging Novel Drug Pipelines and a Realigned Distribution System will Propel the Chinese Pharma Industry

    With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

    $10,000.00
  9. 02 Dec 2019  |  North America

    Growth Opportunities in the Global Pharmaceutical Contract Manufacturing Organization Market (CMO), Forecast to 2024

    Advancements in Continuous Manufacturing Technology, Necessary to Meet New Demand in the Orphan Drugs Segment and Personalized Medicine, Will Give a New Growth Vector to CMOs

    Traditionally, CMOs have thrived by aggregating demand and delivering benefits of economies of scale. However, with the fading era of blockbuster drugs dispensed to large patient pools and shift to precision medicine, focus on niche indications, and increased R&D in biologics, pharma sponsors are increasingly turning to CMOs as strategic partners i...

    $4,950.00
  10. 27 Nov 2019  |  North America

    Global Contract Research Organization (CRO) Market, Forecast to 2024

    Increased Technology Adoption in the Form of eClinical Solutions and Innovative Trial Designs is Expected to Transform the CRO Landscape

    Increased technology adoption in the form of eClinical solutions and innovative trial designs is expected to transform the CRO landscape. Owing to a constantly changing pharmaceutical landscape, the industry is expected to witness a moderate 4% to 5% growth in the next 5 to 7 years, to surpass $1.5 trillion by 2025. In coordination with the indust...

    $4,950.00